Abduljabbar M
Pharmaceuticals (Basel). 2025; 17(12.
PMID: 39770423
PMC: 11676890.
DOI: 10.3390/ph17121581.
Zmaili M, Alzubi J, Alkhayyat M, Albakri A, Alkhalaileh F, Longinow J
Cancers (Basel). 2024; 16(8).
PMID: 38672532
PMC: 11048405.
DOI: 10.3390/cancers16081450.
Shin D, Kim S, Lee H, Lee H, Lee J, Park H
Nat Commun. 2024; 15(1):2789.
PMID: 38555386
PMC: 10981688.
DOI: 10.1038/s41467-024-46336-2.
Nair T
Indian Heart J. 2024; 76 Suppl 1:S44-S50.
PMID: 38195006
PMC: 11019315.
DOI: 10.1016/j.ihj.2023.12.011.
Han R
Mol Ther. 2023; 32(1):1-2.
PMID: 38104562
PMC: 10787164.
DOI: 10.1016/j.ymthe.2023.12.001.
Accuracy and Clinical Impact of Estimating Low-Density Lipoprotein-Cholesterol at High and Low Levels by Different Equations.
Sampson M, Wolska A, Cole J, Zubiran R, Otvos J, Meeusen J
Biomedicines. 2022; 10(12).
PMID: 36551912
PMC: 9776049.
DOI: 10.3390/biomedicines10123156.
Genetic and molecular architecture of familial hypercholesterolemia.
Abifadel M, Boileau C
J Intern Med. 2022; 293(2):144-165.
PMID: 36196022
PMC: 10092380.
DOI: 10.1111/joim.13577.
Efficacy and Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors as Adjuvant Treatments for Patients with Hypercholesterolemia Treated with Statin: A Systematic Review and Network Meta-analysis.
Huang Y, Ho L, Hsu H, Tu Y, Chien K
Front Pharmacol. 2022; 13:832614.
PMID: 35444537
PMC: 9014015.
DOI: 10.3389/fphar.2022.832614.
Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy.
Vinci P, Panizon E, Tosoni L, Cerrato C, Pellicori F, Mearelli F
Int J Mol Sci. 2021; 22(21).
PMID: 34769118
PMC: 8583847.
DOI: 10.3390/ijms222111687.
Comparison of Methods to Estimate Low-Density Lipoprotein Cholesterol in Patients With High Triglyceride Levels.
Sajja A, Park J, Sathiyakumar V, Varghese B, Pallazola V, Marvel F
JAMA Netw Open. 2021; 4(10):e2128817.
PMID: 34709388
PMC: 8554644.
DOI: 10.1001/jamanetworkopen.2021.28817.
The Effect of the PCSK9 Inhibitor Evolocumab on Aldosterone Secretion among High Cardiovascular Risk Patients: A Pilot Study.
Izkhakov E, Shacham Y, Serebro M, Yaish I, Marcus Y, Shefer G
J Clin Med. 2021; 10(11).
PMID: 34198795
PMC: 8201266.
DOI: 10.3390/jcm10112504.
PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD).
Sobati S, Shakouri A, Edalati M, Mohammadnejad D, Parvan R, Masoumi J
Adv Pharm Bull. 2020; 10(4):502-511.
PMID: 33062601
PMC: 7539318.
DOI: 10.34172/apb.2020.062.
A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia.
Sampson M, Ling C, Sun Q, Harb R, Ashmaig M, Warnick R
JAMA Cardiol. 2020; 5(5):540-548.
PMID: 32101259
PMC: 7240357.
DOI: 10.1001/jamacardio.2020.0013.
Integrating DNA sequencing and transcriptomic data for association analyses of low-frequency variants and lipid traits.
Yang T, Wu C, Wei P, Pan W
Hum Mol Genet. 2020; 29(3):515-526.
PMID: 31919517
PMC: 7015848.
DOI: 10.1093/hmg/ddz314.
A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data.
Rana K, Reid J, Rosenwasser J, Lewis T, Sheikh-Ali M, Choksi R
Diabetes Metab Syndr Obes. 2019; 12:1897-1911.
PMID: 31571964
PMC: 6756838.
DOI: 10.2147/DMSO.S167375.
Integrative analysis of loss-of-function variants in clinical and genomic data reveals novel genes associated with cardiovascular traits.
Glicksberg B, Amadori L, Akers N, Sukhavasi K, Franzen O, Li L
BMC Med Genomics. 2019; 12(Suppl 6):108.
PMID: 31345219
PMC: 6657044.
DOI: 10.1186/s12920-019-0542-3.
Discovery of 2,3'-diindolylmethanes as a novel class of PCSK9 modulators.
Winston-McPherson G, Xie H, Yang K, Li X, Shu D, Tang W
Bioorg Med Chem Lett. 2019; 29(16):2345-2348.
PMID: 31227343
PMC: 6690802.
DOI: 10.1016/j.bmcl.2019.06.014.
Inhibition of PCSK9/LDLR Protein-Protein Interaction by Computationally Designed T9 Lupin Peptide.
Lammi C, Sgrignani J, Roda G, Arnoldi A, Grazioso G
ACS Med Chem Lett. 2019; 10(4):425-430.
PMID: 30996774
PMC: 6466515.
DOI: 10.1021/acsmedchemlett.8b00464.
Moderate- and Low-Dose of Atorvastatin Alleviate Cognition Impairment Induced by High-Fat Diet via Sirt1 Activation.
Liu H, Yang J, Wang K, Niu T, Huang D
Neurochem Res. 2019; 44(5):1065-1078.
PMID: 30820818
DOI: 10.1007/s11064-019-02738-z.
Biological Characterization of Computationally Designed Analogs of peptide TVFTSWEEYLDWV (Pep2-8) with Increased PCSK9 Antagonistic Activity.
Lammi C, Sgrignani J, Arnoldi A, Grazioso G
Sci Rep. 2019; 9(1):2343.
PMID: 30787312
PMC: 6382862.
DOI: 10.1038/s41598-018-35819-0.
